Education
About Us
Working with TipRanks
Follow Us
Immutep (IMMP)
NASDAQ:IMMP
IMMP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.32 - $3.34
Previous CloseN/A
Volume50.42K
Average Volume (3M)397.95K
Market Cap
$322.55M
Enterprise Value$124.09M
Total Cash (Recent Filing)AU$54.88M
Total Debt (Recent Filing)AU$9.75M
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Aug 27, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding146,038,960
10 Day Avg. Volume1,024,517
30 Day Avg. Volume397,950
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$12.00Price Target Upside545.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Immutep News
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsImmutep reported positive median overall survival data from its P2b TACTI-003 study evaluating efti + Keytruda in head & neck cancer with negative PD-L1 expression.
Financial StabilityThe company has a strong cash position, expecting to be funded through the end of 2026.
Regulatory ProgressImmutep has requested a meeting with the FDA to discuss the path forward, indicating progress in regulatory engagement.
Bears Say
Market CompetitionThe triple combination of efti, Keytruda, and chemotherapy demonstrated a 12.7 month median progression-free survival, comparing favorably to other outcomes.
Product Development ChallengesINSIGHT-003 data has favorable readthrough to IMMP's lead trial, the soon-to-initiate 750-patient randomized, controlled phase 3 TACTI-004 trial of efti in 1L NSCLC.
Trial ComplexityThe TACTI-004 trial could open up a very large market opportunity for IMMP, as it will be enrolling first line squamous and non-squamous NSCLC patients who are unselected for PD-L1 expression.
---
Ownership Overview
―
Insiders
0.02% Mutual Funds
0.58% Other Institutional Investors
98.96% Public Companies and
Individual Investors
IMMP FAQ
What was Immutep’s price range in the past 12 months?
Immutep lowest stock price was $1.32 and its highest was $3.33 in the past 12 months.
What is Immutep’s market cap?
Immutep’s market cap is $322.55M.
When is Immutep’s upcoming earnings report date?
Immutep’s upcoming earnings report date is Aug 27, 2025 which is in 109 days.
How were Immutep’s earnings last quarter?
Immutep released its earnings results on Feb 26, 2025. The company reported -$0.096 earnings per share for the quarter, beating the consensus estimate of -$0.136 by $0.04.
Is Immutep overvalued?
According to Wall Street analysts Immutep’s price is currently Undervalued.
Does Immutep pay dividends?
Immutep does not currently pay dividends.
What is Immutep’s EPS estimate?
Immutep’s EPS estimate is -0.13.
How many shares outstanding does Immutep have?
Immutep has 146,038,960 shares outstanding.
What happened to Immutep’s price movement after its last earnings report?
Immutep reported an EPS of -$0.096 in its last earnings report, beating expectations of -$0.136. Following the earnings report the stock price went up 1.064%.
Which hedge fund is a major shareholder of Immutep?
Currently, no hedge funds are holding shares in IMMP
---
Immutep Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (545.16% Upside)
$12.00 (545.16% Upside)
Blogger Sentiment
Bullish
IMMP Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 564.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.4%
Last 30 Days ▲ 6.4%
Last 30 Days ▲ 6.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.33%
12-Months-Change
Fundamentals
Return on Equity
-31.16%
Trailing 12-Months
Asset Growth
33.65%
Trailing 12-Months
Company Description
Immutep
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
---
IMMP Stock 12 Month Forecast
Average Price Target
$12.00
▲(545.16% Upside)
Technical Analysis
Astria Therapeutics
―
Y-Mabs Therapeutics
―
iTeos Therapeutics
―
Atea Pharmaceuticals
―
Compass Therapeutics
―
---